Core Insights - The core product of the company, the LinX Continuous Glucose Monitoring System (CGM), received approval for market entry in Brazil on December 23, 2025, targeting both adult and pediatric diabetes patients. This approval is expected to accelerate the company's overseas expansion in 2026, as Brazil is a key market in Latin America with the sixth highest number of diabetes patients globally and the third highest diabetes expenditure worldwide [1] - During the 2025 "Double Eleven" shopping festival, the company's CGM product achieved a GMV growth of 218%, with the second-generation dynamic blood glucose meter's shipment volume increasing by 622.8% year-on-year and new user numbers rising by 300%. The online channel has shown significant growth. According to CITIC Securities, the CGM products are expected to continue high growth in 2026 through a dual-channel strategy of "e-commerce + hospital," while overseas markets are anticipated to maintain high revenue growth due to a low base and expanded insurance access [2] - The company's R&D pipeline includes the second-generation Equil patch insulin pump, a hybrid closed-loop insulin infusion system, and an artificial pancreas system. The pediatric indication (ages 3-17) received approval from the Chinese drug regulatory authority in September 2025, which is expected to contribute to growth in 2026. Additionally, the company is exploring the application of AI large models in the CGM field through collaboration with internal AI teams and research institutions, aiming to upgrade the "device + algorithm + cloud platform" model [3]